Profile data is unavailable for this security.
About the company
Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. It has completed a Phase II trial. The Company’s lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The Company is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia.
- Revenue in AUD (TTM)837.95k
- Net income in AUD-6.01m
- Incorporated2019
- Employees--
- LocationInvex Therapeutics LtdLevel 2, 38 Rowland St, SubiacoPERTH 6008AustraliaAUS
- Websitehttps://invextherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPH Global Ltd | 0.00 | -2.56m | 1.19m | 31.00 | -- | -- | -- | -- | -0.0102 | -0.0126 | 0.00 | -0.0008 | 0.00 | 0.00 | -- | -- | -177.78 | -68.17 | -784.87 | -128.99 | -- | 15.29 | -- | -131.89 | 0.5587 | -4.92 | -- | -- | -99.93 | -74.08 | 19.71 | -- | 1.34 | -- |
| Wellfully Ltd | 1.31m | -1.34m | 1.48m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
| Hexima Ltd | 193.85k | -753.18k | 2.00m | -- | -- | 0.7877 | -- | 10.34 | -0.0045 | -0.0045 | 0.0012 | 0.0152 | 0.0558 | -- | 0.2705 | -- | -21.67 | -72.85 | -26.54 | -193.37 | -- | -- | -388.54 | -213.09 | -- | -- | 0.00 | -- | 271.52 | -19.43 | 80.85 | -- | -- | -- |
| Holista Colltech Limited | 5.95m | -4.81m | 2.51m | 3.00 | -- | -- | -- | 0.4218 | -0.0172 | -0.0172 | 0.0213 | -0.0071 | 1.35 | 2.49 | 4.70 | -- | -111.49 | -42.59 | -347.69 | -63.58 | 56.66 | 56.37 | -82.68 | -39.27 | 0.2845 | -- | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
| Vectus Biosystems Ltd | 86.39k | -2.49m | 4.95m | -- | -- | 2.09 | -- | 57.28 | -0.0467 | -0.0467 | 0.0016 | 0.0445 | 0.0191 | -- | -- | -- | -54.95 | -96.22 | -68.14 | -691.17 | -- | -- | -2,880.80 | -27,693.78 | -- | -439.76 | 0.00 | -- | 69,287.50 | 97.87 | 13.64 | -- | -- | -- |
| Cambium Bio Ltd | -28.22k | -366.01k | 5.13m | -- | -- | -- | -- | -- | -0.1194 | -0.1194 | -0.0092 | -0.3577 | -0.039 | -- | -- | -- | -50.58 | -49.44 | -- | -292.47 | -- | -- | -- | -118.34 | -- | -- | -- | -- | -- | -- | 60.86 | -- | -- | -- |
| Invex Therapeutics Ltd | 837.95k | -6.01m | 5.41m | -- | -- | 1.02 | -- | 6.46 | -0.08 | -0.08 | 0.0112 | 0.0705 | 0.0521 | -- | 2.79 | -- | -37.38 | -- | -40.06 | -- | -- | -- | -717.76 | -- | -- | -- | 0.00 | -- | 379.22 | -- | -96.04 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 3.94m | 761.17k | 6.22m | -- | 7.96 | 1.63 | 7.48 | 1.58 | 0.0054 | 0.0054 | 0.0273 | 0.0264 | 1.02 | -- | 76.13 | -- | 19.64 | -55.72 | 23.29 | -60.89 | -- | -- | 19.34 | -301.54 | -- | 54.64 | 0.00 | -- | 7,292.97 | 179.97 | 89.76 | -- | -- | -- |
| Zelira Therapeutics Ltd | 1.62m | -36.43m | 7.15m | 8.00 | -- | -- | -- | 4.41 | -3.23 | -3.23 | 0.148 | -0.2063 | 0.0848 | 0.185 | 3.55 | -- | -193.14 | -27.71 | -243.04 | -28.81 | 82.28 | -- | -2,278.17 | -508.48 | 0.1488 | -22.80 | -- | -- | -80.95 | -0.3635 | 53.35 | -- | -- | -- |
| Avecho Biotechnology Ltd | 473.55k | -3.44m | 7.92m | 29.00 | -- | 1.24 | -- | 16.73 | -0.0016 | -0.0016 | 0.0002 | 0.002 | 0.0888 | 2.07 | 0.5132 | -- | -64.45 | -47.08 | -75.73 | -55.25 | -9.25 | 78.67 | -725.70 | -156.43 | 8.19 | -- | 0.0267 | -- | -58.07 | -19.42 | -46.71 | -- | -- | -- |
| Island Pharmaceuticals Ltd | 10.28k | -2.37m | 8.62m | -- | -- | 9.75 | -- | 838.54 | -0.026 | -0.026 | 0.0001 | 0.007 | 0.0038 | -- | 0.0318 | -- | -88.77 | -- | -134.02 | -- | -- | -- | -23,100.68 | -- | -- | -- | 0.4433 | -- | -- | -- | -8.58 | -- | -- | -- |
| Bioxyne Ltd | 8.65m | -14.17m | 10.23m | 16.00 | -- | 3.28 | -- | 1.18 | -0.0074 | -0.0074 | 0.0044 | 0.0015 | 1.83 | 6.12 | 10.50 | -- | -302.23 | -22.07 | -418.10 | -28.50 | 38.30 | 45.13 | -165.04 | -39.69 | 1.50 | -- | 0.00 | -- | 1,013.05 | 20.97 | -292.69 | -- | -19.86 | -- |
